糖尿病是一種威脅全世界的慢性病，其發(fā)病率高，影響人們的生活和工作。隨著DNA重組技術(shù)的發(fā)展，長效基礎(chǔ)型胰島素類似物為糖尿病患者帶來了希望，其中甘精胰島素（IGla）、地特胰島素（IDet）以及德谷胰島素（IDeg）是臨床上常用的3種基礎(chǔ)型胰島素，通過改變結(jié)構(gòu)獲得了緩慢的吸收和分布，以及相對(duì)較長的作用時(shí)間，更符合人體分泌胰島素的生理模式。對(duì)這3種胰島素制劑在分子結(jié)構(gòu)以及長效作用機(jī)制、安全性評(píng)價(jià)和藥效作用方面的研究進(jìn)展進(jìn)行總結(jié)。

Diabetes is a kind of worldwide chronic disease with high incidence, which threatens people's lives and work. With the development of DNA recombination technology, long-acting basal insulin analogues bring gospel and hope for patients with diabetes. Insulin glargine (IGla), detemir (IDet) and degludec (IDeg), as three basic types of insulin, commonly used in clinical practice that slowly absorbed and distributed by changing the structure, and relatively long acting time, more fit the physiological model of insulin secretion. Therefore, the existing studies of molecular structure, long-acting mechanism, safety evaluation and pharmacodynamic effects of three kinds of insulin preparations are briefly summarized.

國家重點(diǎn)研發(fā)計(jì)劃（2016YFE0121400），國家自然科學(xué)基金（81473268）